JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

To evaluate the safety and tolerability of JAB-3312 administered in investigational regimens in adult participants with advanced solid tumors.

Must have histologically or cytologically confirmed metastatic or locally advanced solid tumor. Some cohorts must meet specific expression or gene mutation where indicated
Sufficient organ function
Participants must have at least 1 measurable lesion as defined by RECIST v1.1
Must be able to provide an archived tumor sample
ECOG performance status score of 0 or 1.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04720976.

To assess the safety and tolerability and determine the Recommended phase 2 dose (RP2D)

of JAB-3312 in combination with PD1 inhibitor or MEK inhibitor in patients with advanced

solid tumors.

Trial PhasePhase I/II

Trial Typetreatment

Lead OrganizationAllist Pharmaceuticals, Inc.

Description